TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
|Articles|June 29, 2012
Companies React to Top Court's Decision on Health Care
Advertisement
Companies across a variety of sectors related to health care weighed in Thursday after the U.S. Supreme Court upheld the Obama administration's health-care reform law, in one of the court's most highly anticipated decisions in years.
The ruling means different things to different sectors. Medicaid insurers, hospitals and diagnostic test makers stand to gain from the expanded coverage, while insurers and medical device companies are likely to face pressure from certain provisions.
Read the full story:
Source: Morningstar
Advertisement
Related to this article
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.
Teva's Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
2
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
3
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
4
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
5